SR One Capital Management β Full Portfolio
60 tracked investments Β· listed companies and verified rows first
Geneva
Board seatJake NunnΒ· per SEC Form D Β· $3.7M raise Β· filed Apr 2023
BiotechSan Diego, US
Jonathan Leff(Director)Richard Lowenthal(Executive Officer, Director)Pratik Shah(Director)
Board seatRajeev DadooΒ· per SEC Form D Β· $55M raise Β· filed Sep 2021
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for pattern hair loss in men and women.
BiotechHealthtechWest Hartford, US
John W. Childs(Director)Reid Waldman(Executive Officer, Director)Jane Grant-Kels(Director)Vladimir Coric(Director)Timothy Durso(Executive Officer, Director)
Board seatKatarina PanceΒ· per SEC Form D
BiotechWaltham, US
JOSEPH FARMER(Executive Officer)PATRICK GERALD ENRIGHT(Director)HONGBO LU(Director)TOMAS KISELAK(Director)LEON O. MOULDER, JR.(Director)JOHN JACOB ORLOFF(Director)
Board seatJake NunnΒ· per SEC Form D
Avalyn Pharma develops a nebulized inhalation treatment for pulmonary fibrosis designed to improve tolerability compared to existing oral therapies by directly delivering the drug to the lungs.
BiotechMedical Devices
Lyn Baranowski(CEO)in
Biotech company that reached IPO
BiotechCambridge
KEVIN LEE(Executive Officer, Director)FELIX J. BAKER(Director)RICHARD N. KENDER(Director)GREGORY WINTER(Director)STEPHEN SANDS(Director)NIGEL CROCKETT(Executive Officer)
BiotechArlington, US
Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)Kim Brazzell(Executive Officer)Charles McDermott(Executive Officer)
Clinical-stage biopharmaceutical company committed to developing best-in-class novel therapy for hypertension treatment.
BiotechRadnor, US
Brian Taylor Slingsby(Director)Olivier Litzka(Director)Derek DiRocco(Director)Adam Levy(Executive Officer)Jon Congleton(Executive Officer, Director)Srinivas Akkaraju(Director)
Developing allogeneic or off-the-shelf cell therapies for cancer and auto-immune disease based on Natural Killer cells.
South San Francisco, US
South San Francisco, US
Board seatLaetitia SchwabMatthew R. PattersonΒ· per SEC Form D
La Jolla, US
Peppi Presit(Director)Richa Nand(Executive Officer)Bradley Bolzon(Director)Ray Stevens(Director)Simon Nebel(Director)Simeon George(Director)
Board seatSimeon J. GeorgeΒ· per SEC Form D Β· $2.5M raise Β· filed Jan 2017
BiotechBasel
Kurt von Emster(Director)Sven Ante Lundberg(Executive Officer)Thomas Woiwode(Director)Ali Behbahani(Director)Rodger Novak(Executive Officer, Director)Pablo Cagnoni(Director)
Board seatSimeon J. GeorgeΒ· per SEC Form D Β· $35M raise Β· filed Nov 2016
HealthtechMenlo Park, US
LUIS PENA(Executive Officer)CHRISTOPHER GRIFFITH(Executive Officer)KATHLEEN SEBELIUS(Director)DAVID E. COHEN(Director)FRED CRAVES(Director)THOMAS G. WIGGANS(Executive Officer, Director)
Board seatJake NunnΒ· per SEC Form D Β· $1M raise Β· filed Dec 2018
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)Ivan Trifunovich(Director)John Wesley(Director)
Board seatRajeev DadooΒ· per SEC Form D Β· $80M raise Β· filed Mar 2022
BiotechWaltham, US
Michael Gutch(Executive Officer)John Mueller(Executive Officer)Heather Behanna(Director)David Altarac(Executive Officer)David Meek(Director)David Hastings(Director)
Board seatHeather BehannaΒ· per SEC Form D Β· $25M raise Β· filed Sep 2020
BiotechCambridge, US
Jean-Francois Formela(Director)Rick Lundberg(Executive Officer)Alan Crane(Director)David Madden(Director)Marian Nakada(Director)Brian Gallagher(Director)
Board seatRajeev DadooΒ· per SEC Form D Β· $20.2M raise Β· filed May 2020
Creating next generation precision medicines for patients with cancer and inflammatory diseases by targeting key signaling nodes.
BiotechCambridge, US
Valerie Odegard(Director)Jill Carroll(Director)Carl Gordon(Director)Jeffrey Leiden(Director)Charles Baum(Director)Gary D Glick(Executive Officer, Director)
Board seatJill CarrollΒ· per SEC Form D
BiotechWaltham, US
John Hennessy(Executive Officer)Jens Eckstein(Director)Karen Hong(Director)James W. Broderick(Executive Officer, Director)James Lee(Director)William Burkoth(Director)
Board seatRajeev DadooΒ· per SEC Form D
San Diego, US
Board seatJake NunnΒ· per SEC Form D Β· $34.6M raise Β· filed Dec 2021
Endologix develops medical devices for treating vascular disease, including the DETOURβ’ System for endovascular aortic repair (EVAR) procedures.
HealthtechMedical DevicesSanta Rosa, US
DOUGLAS A. ROEDER(Director)SHARI L. O'QUINN(Executive Officer)MICHAEL V. CHOBOTOV(Executive Officer)MICHAEL R. KRAMER(Executive Officer)RYAN D. DRANT(Director)DANIEL J. MOORE(Director)
Board seatJake NunnΒ· per SEC Form D Β· $10M raise Β· filed Aug 2015
BiotechPalo Alto, US
Anna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)
BoardJill Carroll(Director)
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.
BiotechDigital HealthHealthtechMedical Devices
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.
BiotechHealthtechCopenhagen, DK
Jens Juul Holst(Founder)Mette Rosenkilde(Founder)
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Lewis T. Rusty Williams(Director)Jill Carroll(Director)David Lubner(Director)Ali Behbahani(Director)Rami Elghandour(Executive Officer, Director)
Biotheryx discovers and develops targeted protein degrader drugs designed to treat cancer and inflammatory diseases.
BiotechMedical DevicesSan Diego, US
Kyle Chan, PhD(Executive Officer)David Stirling, PhD(Executive Officer, Director)Louis DeGennaro, PhD(Director)Lawrence Zaslow(Executive Officer, Director)Frank Mercurio, PhD(Executive Officer)
HealthtechLondon
Gary Glick(Director)Rishi Gupta(Director)Nihal Sinha(Director)Lakshyaditya Singh Aithani(Executive Officer, Director)Muzammil Mansuri(Director)
Boston, US
Provides functional information about mutations and drug responses to enable precision oncology treatments.
Allosteric drug discovery unlocking on/off switches in proteins.
Rezo Therapeutics is a drug discovery and development company focused on oncology and inflammation therapeutic areas.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Nevan Krogan(Co-Founder)Sourav Bandyopadhyay(Co-Founder)Norbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)George Scangos(Co-Founder)Kevan Shokat(Co-Founder)
Clinical-stage company developing novel therapies for orphan renal diseases.
A drug discovery company advancing novel medicines targeting unexplored areas of immune biology, with a focus on cancer treatments.
Biotech
Yiming Li(Director)Axel Hoos(Director)Terry Rosen(Director)Aaron Ring(Executive Officer, Director)Jake Bauer(Executive Officer, Director)Beatrice McQueen(Executive Officer)
BiotechCambridge, US
Hui Tian(Executive Officer, Director)Madgalene Moran(Executive Officer, Director)
BoardKarin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.